SEC Form 4 · accession 0001203311-16-000112
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Jul 6, 2016
Accepted (ET)
Jul 7, 2016 · 8:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 6, 2016 | M | 5,172 | $4.45 | A | 561,287 | D | |
| Common StockF3,F1 | Jul 6, 2016 | S | 5,172 | $40.78 | D | 556,115 | D | |
| Common StockF1 | Jul 6, 2016 | M | 2,446 | $4.45 | A | 558,561 | D | |
| Common StockF4,F1 | Jul 6, 2016 | S | 2,446 | $40.10 | D | 556,115 | D | |
| Common Stock | holding | — | — | — | 27,945 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $4.45 | Jul 6, 2016 | M | 5,172 | D | — | Sep 5, 2016 | Common Stock | 5,172 | 17,675 | D |
| Non-Qualified Stock Option (right to buy)F5 | $4.45 | Jul 6, 2016 | M | 2,446 | D | — | Sep 5, 2016 | Common Stock | 2,446 | 15,229 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $40.51 to $41.07. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $39.50 to $40.50. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 9/06/07 and monthly thereafter until all the shares were fully vested on 9/06/10.